1. Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris. An Bras Dermatol 2019; 94(3): 264–278.
2.
Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Immunol Allergy Clin North Am 2012; 32(2): 233–243.
3.
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res 2018; 66(2): 255–270.
4.
Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res 2015; 307(4): 291–298.
5.
Buonavoglia A, Leone P, Dammacco R, et al. Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy. Autoimmun Rev 2019; 18(4): 349–358.
6.
Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol 2019; 44(7): 740–746.
7.
Lee YB, Lee JH, Lee SY, et al. Incidence and death rate of pemphigus vulgaris and pemphigus foliaceus in Korea: a nationwide, population-based study (2006–2015). J Dermatol 2018; 45(12): 1396–1402.
8.
Iamaroon A, Boonyawong P, Klanrit P, et al. Characterization of oral pemphigus vulgaris in Thai patients. J Oral Sci 2006; 48(1): 43–46.
9.
Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Clinical features and course of pemphigus in Thai patients. Asian Pac J Allergy Immunol 2011; 29(2): 161–168.
10.
Zhu X, Pan J, Yu Z, et al. Epidemiology of pemphigus vulgaris in the Northeast China: a 10-year retrospective study. J Dermatol 2014; 41(1): 70–75.
11.
Yavuz IH, Yavuz GO, Bayram I, et al. Pemphigus in the eastern region of Turkey. Post Dermatol Alergol 2019; 36(4): 455–460.
12.
Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Acta Derm Venereol 2017; 97(9): 1095–1099.
13.
Serwin AB, Koper M, Flisiak I. Incidence of pemphigus vulgaris and pemphigus foliaceus in North-East Poland (Podlaskie Province) – a 15-year (2001–2015) bicentric retrospective study. Int J Dermatol 2018; 57(8): 933–937.
14.
Baican A, Chiorean R, Leucuta DC, et al. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet J Rare Dis 2015; 10: 48.
15.
González DA, Díaz BB, Rodríguez Pérez Mdel C, et al. Sex hormones and autoimmunity. Immunol Lett 2010; 133(1): 6–13.
16.
Tiniakou E, Costenbader KH, Kriegel MA. Sex-specific environmental influences on the development of autoimmune diseases. Clin Immunol 2013; 149(2): 182–191.
17.
Naseer SY, Gill L, Shah J, et al. Gender-based variability in disease presentation in pemphigus vulgaris. J Drugs Dermatol 2014; 13(10): 1225–1230.
18.
Ohki M, Kikuchi S. Nasal, oral, and pharyngolaryngeal manifestations of pemphigus vulgaris: endoscopic ororhinolaryngologic examination. Ear Nose Throat J 2017; 96(3): 120–127.
19.
Santoro FA, Stoopler ET, Werth VP. Pemphigus. Dent Clin North Am 2013; 57(4): 597–610.
20.
Sar-Pomian M, Rudnicka L, Olszewska M. The significance of scalp involvement in pemphigus: a literature review. Biomed Res Int 2018; 2018: 6154397.
21.
Delavarian Z, Layegh P, Pakfetrat A, et al. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent 2020; 12(5): e440–e445.
22.
Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res 2018; 310(2): 95–106.
23.
Sullivan TP, Elgart GW, Kirsner RS. Pemphigus and smoking. Int J Dermatol 2002; 41(8): 528–530.
24.
Popescu IA, Statescu L, Vata D, et al. Pemphigus vulgaris – approach and management. Exp Ther Med 2019; 18(6): 5056–5060.
25.
Daltaban Ö, Özçentik A, Akman Karakaş A, et al. Clinical presentation and diagnostic delay in pemphigus vulgaris: a prospective study from Turkey. J Oral Pathol Med 2020; 49(7): 681–686.